Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Rate of the Pompe Disease Market from 2024 to 2033?
In recent times, the market size for Pompe disease has experienced stable growth. It is projected that it will rise from $1.66 billion in 2023 to $1.73 billion in 2024, indicating a compound annual growth rate (CAGR) of 4.2%. The growth seen in the earlier period is due to factors such as heightened awareness and diagnosis, benefits and special status allocated to orphan drugs, worldwide collaborations and research efforts, along with the presence of patient advocacy and support groups.
Anticipated robust expansion is on the cards for the Pompe disease market in the ensuing years. This market is pegged to swell to $2.13 billion by 2028, marking a compound annual growth rate (CAGR) of 5.3%. The factors expected to contribute to this growth spurt in the prediction horizon include continuous research and development, the increment of newborn screening schemes, gene therapy progress, a surge in worldwide investment in rare illnesses, patient-focused drug development, multiplication of clinical trials and research efforts, and market focus on personalized medicine strategies. The forecast period will likely be characterized by product innovation, technological progress, establishment of patient aid programs, increasing uptake of telemedicine for administering patient care, and alliances to widen access programs.
Claim Your Free Sample of the Global Pompe Disease Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp
What Key Factors Are Fueling the Growth of the pompe disease Market?
The surge in the number of pompe disease cases is forecasted to enhance the growth of the pompe disease market. Also referred to as glycogen storage disease type II or acid maltase deficiency, pompe disease is a unique genetic condition distinguished by the accumulation of glycogen, a complicated sugar molecule, in multiple body tissues, predominantly muscles and organs. Protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion are employed in treating pompe disease. With the number of pompe disease cases on the rise, the pompe disease market is anticipated to experience significant growth. For example, in June 2022, as per the European Medicines Agency Highlights, a European-based intergovernmental entity, approximately 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset individuals in Europe potentially suffer from Pompe disease due to mutations, as indicated by the maximum birth rate of 11.6 per 100,000. Consequently, the prevalence surge of pompe disease is accelerating the growth of the pompe disease market.
What Are the Major Segments of the Pompe Disease Market?
1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types
2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis
3) By Route of Administration: Oral, Parenteral, Other routes of administrations
4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies
5) By End Users: Hospitals / Clinics, Pharmaceuticals, Researchers, Other End-Users
What New Trends Are Transforming the Pompe Disease Market?
Trend 1 underlines product modernization as a critical element growing in popularity within the pompe disease industry. Leading corporations within the sector are harnessing innovations in order to reinforce their dominance in the marketplace. For instance, in September 2023, the U.S. Food and Drug Administration (FDA) authorized Amicus Therapeutics, an American biopharmaceutical company, to introduce Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules. This dual therapy is formulated for adults suffering from late-onset Pompe disease (LOPD) who weigh 40 kg or more. This unique combination features Pombiliti as a reconstituted human GAA enzyme (rhGAA) engineered to maximize uptake in muscle cells, while Opfolda functions as an enzyme stabilizer to maintain the enzyme in the blood. This FDA endorsement emphasizes the importance of progress in the fields of science and medicine.
Order Now for Fast Delivery of Your Pompe Disease Market Report!
https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report
Which Regions Are Driving Growth in the Pompe Disease Market?
North America was the largest region in the pompe disease market in 2023. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The Pompe Disease Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the pompe disease market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Pompe Disease Market Include
1. Pompe Disease Market Executive Summary
2. Pompe Disease Market Segments
3. Pompe Disease Market Size And Template Market Growth Rate
4. Key Pompe Disease Market Trends
5. Major Pompe Disease Market Drivers
……
25. Key Mergers And Acquisitions In The Pompe Disease Market
26. Top Pompe Disease Companies
27. Pompe Disease Market Opportunities And Strategies
28. Pompe Disease Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Crohn’s Disease Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
Sickle Cell Disease Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report
Inflammatory Bowel Disease Treatment Global Market Report 2024
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
